Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328148 | Acta Haematologica Polonica | 2013 | 5 Pages |
Abstract
The most common cause of isolated thrombocytopenia is primary immune thrombocytopenia (ITP). For patients failing initial corticosteroid-based treatment and with refractory ITP post-splenectomy, thrombopoietin receptor agonists are indicated. Two of this thrombopoiesis-stimulating agents have been approved for use in ITP - eltrombopag, formulated for oral administration, once a day and romiplostim, which is administered weekly as a subcutaneous injection.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Janusz KÅoczko, Anna Szumowska, Marzenna Galar,